Link Silicon Valley
The fastest way to connect to the people, companies and capital of Silicon Valley
Free 30 Day Trial Account
Sign Up | Log In
My Lists

CareDx  (Stock symbol: CDNA )

1 Tower Place
South San Francisco, CA 94080
Website Company Summary Management Team

CEO: Reginald Seeto (11/2/2021)
President/COO/Operations: Paul Ciccolella (10/31/2018) ; Mitchell J Nelles (01/02/2007)
General Management: James P Yee (08/16/2006)
Finance: Theresa Yu (9/30/2014) ; Ankur Dhingra (03/31/2021)
Technology: Robert Woodward (1/31/2018) ; John Sninsky
Business Development: Sasha King
General Counsel/Legal: Ilan Feuchtwang

Outside board: (May no longer be on the board) Ralph Snyderman (Executive Dean Professor) William Hagstrom (Crescendo Bioscience) Peter Maag (CareDx Former President/CEO) George Bickerstaff (MM Dillon & Co Managing Director) Amy Abernethy (Flatiron Health Chief Medical Officer) Art Torres (California State Assembly) Michael Goldberg (Mohr, Davidow Ventures) Fred Cohen (TPG Growth)
Advisory board: Jay Wohlgemuth (VIA Pharmaceuticals VP R&D) Mary K Krow (Cornell University Professor) Risa Stack (Kleiner Perkins Partner) Jeffrey A Bluestone (UCSF Diabetes Center Director Professor) Rob Tibshirani (Stanford University Professor)

Business description: CareDx is transforming Transplant Patient Care Through Novel Surveillance Management Solutions. CareDx, Inc. is dedicated to improving the lives of organ transplant patients through non-invasive diagnostics. By combining the latest advances in genomics and bioinformatics technology, with a commitment to generating high quality clinical evidence through trials and registries, CareDx is at the forefront of organ transplant surveillance and pre-transplant HLA typing solutions. AlloSure is the first and only non-invasive blood test that directly measures allograft injury and identifies the probability of active rejection to better manage kidney transplant patients. AlloSure is a clinical-grade, proprietary Next-Generation Sequencing (NGS) based test to detect donor-derived cell-free DNA (dd-cfDNA) in order to identify organ injury in kidney transplant recipients. AlloSure is analytically validated as a sensitive, specific, and precise measurement of dd-cfDNA. AlloSure detects active rejection (acute active ABMR, chronic active ABMR, or TCMR) with high accuracy, outperforms serum creatinine in kidney transplant recipients, and is highly sensitive in distinguishing ABMR from no ABMR. AlloSure is performed in the CareDx CLIA-certified laboratory.
Partners include: Bristol-Myers Squibb ;  LabCorp ;  University of Minnesota

Rounds: 6
Recent Fundings: Aug 2009   Jun 2008
Capital raised: 123.8M
Last Round: 14.4M
Ownership: Public   Ipo Filing
Stock Symbol: CDNA

Last Tweets


Last Mentions

Record updated: Nov 2021
Sector: Biotech
Year Founded: 2000
Headcount: 501-600 as of Nov 2021
Rounds: 6
Recent Fundings: Aug 2009   Jun 2008
Capital Raised: 123.8M
Last Round: 14.4M
Ownership: Public   Ipo Filing
Stock Symbol: CDNA